Literature DB >> 31606775

Cardiovascular risk factors' behavior during the early stages of the disease, in Hispanic rheumatoid arthritis patients: a cohort study.

Irazú Contreras-Yáñez1, Guillermo Guaracha-Basáñez1, Virginia Pascual-Ramos2.   

Abstract

Rheumatoid arthritis (RA) patients from Latin America present distinctive characteristics relevant when assessing their cardiovascular (CV) risk. The objective was to monitor CV risk factor behavior in the early stages of the disease and to identify predictors of major CV outcomes (MACE). A recent-onset RA cohort was initiated in 2004; data from 185 patients with ≥ 1 year of follow-up were analyzed. Patients underwent prospective assessments of CV risk factors. Incident MACE were confirmed according to standardized definitions. Appropriated statics was used based on the distribution of the variables. At baseline, patients were primarily middle-aged females (87.6%), with active disease (69.7%). Most prevalent CV risk factors were C-reactive-protein > 1 mg/L (90.3%), Castelli ratio > 3 (83.8%), and low-high-density lipoprotein levels (73.5%). The number of patients with an incident CV risk factor after 1 year was higher for a Castelli ratio > 3 (23%), low-high-density lipoprotein serum cholesterol (16.3%), high total serum cholesterol (10.6%), and BMI ≥ 30 kg/m2 (10%). A minority of patients met the age-range criteria for the application of ACC/AHA 2013 criteria and Reynolds Risk Score (45.8% and 34.1%, respectively). Fifteen patients were classified with high-CV risk during the first year of follow-up, according to ACC/AHA 2013 criteria. Until June 2018, the cohort underwent 1358 patient/years follow-up; six patients developed incidental MACE; high-CV risk at baseline failed to predict MACE. Recent-onset RA Hispanic patients present a distinctive pattern and first-year behavior of CV risk factors. During follow-up, few patients developed incidental MACE.

Entities:  

Keywords:  Cardiovascular diseases; Rheumatoid arthritis; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31606775     DOI: 10.1007/s00296-019-04451-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  48 in total

1.  Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance Using Cardiovascular Quality Indicators.

Authors:  Claire E H Barber; John M Esdaile; Liam O Martin; Peter Faris; Cheryl Barnabe; Selynne Guo; Elena Lopatina; Deborah A Marshall
Journal:  J Rheumatol       Date:  2016-08-01       Impact factor: 4.666

2.  Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.

Authors:  Tuomas Rannio; Juha Asikainen; Arto Kokko; Pekka Hannonen; Tuulikki Sokka
Journal:  J Rheumatol       Date:  2016-02-15       Impact factor: 4.666

3.  Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations.

Authors:  Jette Primdahl; Joan Clausen; Kim Hørslev-Petersen
Journal:  Ann Rheum Dis       Date:  2013-07-12       Impact factor: 19.103

4.  Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study.

Authors:  Pablo Lázaro; Nekane Murga; Dolores Aguilar; Miguel A Hernández-Presa
Journal:  Rev Esp Cardiol       Date:  2010-12       Impact factor: 4.753

Review 5.  Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.

Authors:  George D Kitas; Sherine E Gabriel
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

6.  Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.

Authors:  Mario H Cardiel; Bernardo A Pons-Estel; Mónica P Sacnun; Daniel Wojdyla; Verónica Saurit; Juan Carlos Marcos; María Raquel C Pinto; Ana Beatriz Cordeiro de Azevedo; Inês Guimarães da Silveira; Sebastião C Radominski; Antônio C Ximenes; Loreto Massardo; Francisco Ballesteros; Adriana Rojas-Villarraga; Rafael Valle Oñate; Margarita Portela Hernandez; Jorge A Esquivel-Valerio; Ignacio García-De La Torre; Vianna J Khoury; Alberto Millán; Enrique Roberto Soriano
Journal:  J Clin Rheumatol       Date:  2012-10       Impact factor: 3.517

7.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

Authors:  J Antonio Aviña-Zubieta; Hyon K Choi; Mohsen Sadatsafavi; Mahyar Etminan; John M Esdaile; Diane Lacaille
Journal:  Arthritis Rheum       Date:  2008-12-15

Review 8.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

9.  Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.

Authors:  Antonio Naranjo; Tuulikki Sokka; Miguel A Descalzo; Jaime Calvo-Alén; Kim Hørslev-Petersen; Reijo K Luukkainen; Bernard Combe; Gerd R Burmester; Joe Devlin; Gianfranco Ferraccioli; Alessia Morelli; Monique Hoekstra; Maria Majdan; Stefan Sadkiewicz; Miguel Belmonte; Ann-Carin Holmqvist; Ernest Choy; Recep Tunc; Aleksander Dimic; Martin Bergman; Sergio Toloza; Theodore Pincus
Journal:  Arthritis Res Ther       Date:  2008-03-06       Impact factor: 5.156

10.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.